Federal Register / Vol. 66, No. 94 / Tuesday, May 15, 2001 / Notices 26871

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Glycoprotein Hormone

Superagonists

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 09/185,408 filed

May 6, 1996 entitled ‘‘Glycoprotein

Hormone Superagonists’’, to N.V.

Organon, having a place of business in

The Netherlands. The field of use may

be limited to the treatment of human

infertility. The United States of America

is the assignee of the patent rights in

this invention. This announcement

replaces two previous notices to grant

an exclusive license to this

technology—64 FR 38685, July 19, 1999

and 65 FR 5878–5879, February 7, 2000.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before July

16, 2001 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Marlene Shinn, Technology

Licensing Specialist, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852–3804;

Telephone: (301) 496–7056, ext. 285;

Facsimile: (301) 402–0220; e-mail:

MS482M@NIH.GOV.

SUPPLEMENTARY INFORMATION: This

invention relates generally to modified

glycoprotein hormones and specifically

to modifications to a human

glycoprotein, which create superagonist

activity. Glycoprotein hormones

comprise a family of hormones, which

are structurally related heterodimers

consisting of a species common α subunit and a distinct β sub-unit that

confers the biological activity for each

hormone.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: May 7, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–12124 Filed 5–14–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: ‘‘Optical Fiber Probe and

Methods for Measuring Optical

Properties’’

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license to practice the inventions

embodied in: U.S. Patent Application

No. 09/428,832 ‘‘Optical Fiber Probe

and Methods for Measuring Optical

Properties’’ filed October 28, 1999,

taking priority from U.S. Provisional

Application No. 60/105,945 filed

October 28, 1998, to AzurTec, Inc. with

a place of business in Newtown,

Pennsylvania. The United States of

America is an assignee to the patent

rights of these inventions.

The contemplated exclusive license

may be limited to the use of

metachromatic dye staining in the

diagnosis and treatment of cervical, oral

pharyngeal, bladder and gastrointestinal

cancer.

DATES: Only written comments and/or

applications for a license that are

received by the NIH Office of

Technology Transfer on or before July

16, 2001 will be considered.

ADDRESSES: Requests for a copy of the

patent application, inquiries, comments

and other materials relating to the

contemplated license should be directed

to: Dale D. Berkley, Ph.D., J.D.

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Telephone: (301) 496–

7056, ext. 223; Facsimile: (301) 402–

0220; E-mail: berkleyd@od.nih.gov. A

signed Confidential Disclosure

Agreement will be required to receive

copies of the patent application.

SUPPLEMENTARY INFORMATION: The

invention is a probe for the

characterization of optical scattering

and absorption properties of a sample

illuminated by an illumination fiber

situated next to at least two collection

fibers. The collection fibers are spaced

at various distances from the

illumination fiber, and fluorescence

spectra are typically measured using the

invention. Linear and concentric

arrangements of the collecting fibers are

employed in the invention to obtain an

intensity distribution of diffusely

reflected light, which distribution can

be used to distinguish samples of

different tissues for medical purposes.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: May 7, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–12125 Filed 5–14–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.